IMUX — IMMUNIC, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1280776 ·
Last close
$12.97
Market Cap
$176.67M
52W High
$15.10
52W Low
$8.50
ADV30
322,616
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -33,235,000 | -32,588,000 | 189,742,000 | 186,629,000 | 38,509,000 |
| Dec 2025 | 0 | — | -23,327,000 | -19,300,000 | 24,052,000 | 15,483,000 | 30,725,000 |
| Sep 2025 | 0 | — | -25,993,000 | -25,579,000 | 40,704,000 | 35,132,000 | 30,205,000 |
| Jun 2025 | 0 | — | -27,083,000 | -26,820,000 | 61,429,000 | 55,310,000 | 27,518,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-85,806,000
Investing CF
$-161,000
Financing CF
$65,577,000
CapEx
$-161,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-608,571,000
Inventory
—
Receivables
$4,122,000
ST Investments
—
EBIT TTM
$-103,228,000
Pretax Income TTM
$-97,172,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,228,000 | -97,172,000 | 24,052,000 | 30,725,000 | — | -85,806,000 |
| Dec 2024 | 0 | -98,052,000 | -100,507,000 | 40,868,000 | 22,439,000 | — | -84,766,000 |
| Dec 2023 | 0 | -99,223,000 | -93,612,000 | 54,299,000 | 25,368,000 | — | -70,828,000 |
| Dec 2022 | 0 | -86,518,000 | -120,407,000 | 127,753,000 | 14,069,000 | — | -65,144,000 |
TTM Snapshot
Revenues TTM
$1,782,000
NetIncome TTM
$-87,653,000
OpCashFlow TTM
$0
Assets (Latest)
$40,868,000
Forward EPS
$-3.55
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $12.97 · call volume: 40 · put volume: 31
Expected Move to 2026-06-18:
±$2.70
(20.82%) —
implied range
$10.27 –
$15.67
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KRRO | Korro Bio, Inc. | $177.83M | $12.33 | — |
| NGEN | NERVGEN PHARMA CORP. | $175.07M | $2.13 | — |
| MIST | Milestone Pharmaceuticals Inc. | $174.30M | $1.40 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $180.05M | $4.80 | — |
| ANTX | AN2 Therapeutics, Inc. | $170.36M | $4.73 | — |
News headlines (Yahoo Finance, 1h cache)
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
2026-05-19 13:33 · Yahoo
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
2026-05-19 10:30 · Yahoo
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?
2026-05-17 14:31 · Yahoo
Immunic advances Phase 3 MS program, eyes topline data by year-end
2026-05-13 13:04 · Yahoo
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 10:30 · Yahoo
Immunic CEO on Q1 highlights, new appointments and upcoming milestones
2026-05-07 12:47 · Yahoo
Immunic to Participate in Investor and Medical Conferences in May
2026-04-30 10:30 · Yahoo
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
2026-04-28 12:40 · Yahoo
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
2026-04-28 10:30 · Yahoo
Immunic to implement 1-for-10 reverse stock split
2026-04-23 12:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.